載入中
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
前收盤價
US$1.89
+US$0.06 · +3.28%
盤中時間採用ET。市場資料可能有所延遲。
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
日內區間
目前US$1.89
52週區間
目前US$1.89
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
46
合理估值
情緒
45
多空交錯
風險
63
高風險
動能
79
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
日內區間
目前US$1.89
52週區間
目前US$1.89
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5萬 USD | 1.4萬 USD | 15.5萬 USD | 37.4萬 USD | 18.1萬 USD |
| 毛利 | 5萬 USD | 1.4萬 USD | 15.5萬 USD | 37.4萬 USD | 18.1萬 USD |
| 研究與開發 | 2065.9萬 USD | 3316.6萬 USD | 2027.3萬 USD | 1706.7萬 USD | 2054.3萬 USD |
| 銷售、一般及管理費用 | 1026萬 USD | 948.3萬 USD | 962.3萬 USD | 925.8萬 USD | 879.1萬 USD |
| 營業費用 | 3091.9萬 USD | 4264.9萬 USD | 2989.6萬 USD | 2632.5萬 USD | 2933.4萬 USD |
| 利息收入 | 85萬 USD | — | — | — | — |
| 折舊和攤銷 | 8.4萬 USD | 55.3萬 USD | 2974.1萬 USD | 2595.1萬 USD | 2915.3萬 USD |
| 營業利益 | −3086.9萬 USD | −4263.5萬 USD | −2974.1萬 USD | −2595.1萬 USD | −2915.3萬 USD |
| 淨利 | −4593.3萬 USD | −4208.2萬 USD | −3000.8萬 USD | −2729.9萬 USD | −3034萬 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$22.00
上漲空間 1064.02%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI112.76萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF45.08萬0.00%954億 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC14.14萬0.01%13.17億 USD0.60%US$183+0.11%
U.S. Micro Cap Portfolio ETFDFMC1.06萬0.00%75.58億 USD0.43%US$57.813+0.20%
Dimensional - US Small Cap ETFDFAS7808.610.00%338.69億 USD0.31%US$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Small Cap ETFDFASAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
